News|Articles|October 3, 2023

A Look Back at the 2022 Annual Psychiatric Times® World CME Conference

Get ready for our upcoming virtual, interactive conference with some highlights from 2022.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Digital Apps for Substance Use Reduction: Discussion With InvestigatorJon-Patrick Allem, PhD

ByJon-Patrick Allem, PhD

November 27th 2025

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

ByAndrew Nguyen, MD, MSc,Ayal Schaffer, MD, FRCPC

November 26th 2025

Using Long-Acting Injectables to Reduce Rates of Relapse: Insights From Erin Crown, MHS, PA-C, Psych-CAQ

ByErin Crown, MHS, PA-C, Psych-CAQ

November 25th 2025

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

ByJessica Walters

November 24th 2025

transcranial magnetic stimulation depression treatment

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

ByRachel Rohaidy, MD

November 24th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

A Look Back at the 2022 Annual Psychiatric Times® World CME Conference

Newsletter

Related Content

Digital Apps for Substance Use Reduction: Discussion With InvestigatorJon-Patrick Allem, PhD

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

Using Long-Acting Injectables to Reduce Rates of Relapse: Insights From Erin Crown, MHS, PA-C, Psych-CAQ

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

The Hybrid Model: Humans & Chatbots Working Together

The Truth About Insomnia and Melatonin: Natural Does Not Always Mean Harmless

Interrelation of Hormones and Adult ADHD

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

Lithium Reduces Risk of Suicide and Recurrent Episodes of Bipolar and Major Depressive Disorders